Big Pharma: Desacuerdos sobre costos de I+D.

Click sobre imagen para ampliar

The average cost of bringing a drug to market has also increased by 21% compared to last year to $1.05 billion, yet the study says the commercial value of these projects are no greater than a year ago.

The study adds there is a wide variation from company to company, from the lowest cost of bringing a drug to market being $439 million to the highest being $2.47 billion. (Ver)

Bien reciente:


Ver también:

Desmitificando el costo de desarrollo de un nuevo medicamento.

Measuring the return from innovation: Is R&D earning its investment?